CEO Corner

CEO Corner articles are written by presidents or CEOs of biopharmaceutical or medical device companies that create a drug or device. These articles discuss global industry trends, experiences, and challenges that biopharma CEOs and presidents can relate to and should be aware of.  

  • How Moving Up Through The Ranks Can Shape A Biotech CEO
    How Moving Up Through The Ranks Can Shape A Biotech CEO

    All CEOs of small, publicly traded biotechs are required to wear many hats in the office every day. That’s why having a leader with a diverse background and experience in a variety of functional areas is an asset. Here we look at some of the various areas of expertise that can help create a more diverse C-suite executive.

  • Successfully Transforming An Organization: An Active Approach
    Successfully Transforming An Organization: An Active Approach

    Rich Daly, Chairman & CEO of Neuralstem, Inc., pens this month column and gives some enlightening anecdotes about what it takes to make "transformational" changes at a biopharma company.

  • Collaborating To Stem The Tide Of Emerging Antimicrobial Resistance
    Collaborating To Stem The Tide Of Emerging Antimicrobial Resistance

    Jeffrey Stein, Ph.D., president and CEO of Cidara Therapeutics, discusses what needs to be done now by drug companies and healthcare providers alike to stem the tide of emerging antimicrobial resistance, including collaboration to address market barriers.

  • The Biotech CEO — It’s Not For Everyone
    The Biotech CEO — It’s Not For Everyone

    I’ve often described the challenge of developing new medicines as analogous to the difficulty of climbing the highest mountains on Earth. If one follows that analogy, then seeking to develop a new treatment for Alzheimer’s disease is like climbing K2, the second highest peak — in winter. That feat has not yet been accomplished, and those who aspire to do so describe it as their last frontier. Similarly, the brain is one of the last frontiers in medicine and drug development.

  • The Case For A Healthcare Futures Market
    The Case For A Healthcare Futures Market

    Now is the time to develop a novel financial instrument which will provide risk transfer, transparency, and more certainty. A futures market in healthcare is a product whose time has come.

  • Understanding The Many Faces Of Innovation
    Understanding The Many Faces Of Innovation

    By its very definition, innovation may travel long and painful paths, require repeated failure, and invite numerous mistakes to gather experience for bringing forward something new. Lady luck also intervenes occasionally, as well.

  • Why More Incentives Are Needed To Tackle Antibiotic Resistance
    Why More Incentives Are Needed To Tackle Antibiotic Resistance

    Antibiotic resistance is a real and immediate threat that is beginning to garner the global attention it needs and deserves. During a meeting of the United Nations in September 2016, the entire General Assembly — 193 nations — reaffirmed its commitment to developing national action plans on combatting antibiotic resistance.

  • An Insider’s View Of Life Outside The Academic Gilded Cage
    An Insider’s View Of Life Outside The Academic Gilded Cage

    There is a lyric from an old Bob Seger song in which the aging songwriter, lamenting the loss of his youthful prowess once filled with vim and vigor, wonders where the time went (“20 years now; where’d they go; 20 years; I don’t know”).

  • Can Financial Markets Solve The Ever-Increasing Costs of Healthcare?
    Can Financial Markets Solve The Ever-Increasing Costs of Healthcare?

    Why hasn't the healthcare industry evolved into vertical segmentation like other industries? Until now, it's because there has been no systematic way to hedge/transfer either institutional or operating risk in the healthcare system because information gathering and delivery is generally limited and poorly organized.

  • Biotechnology: The Hope For Rare Diseases
    Biotechnology: The Hope For Rare Diseases

    John Crowley, chairman and CEO of Amicus Therapeutics discusses why biotechs in the rare disease space face particularly unique and fundamental challenges.

More From CEO Corner

BEYOND THE PRINTED PAGE

  • Daniel Skovronsky – From Grad Student, To CEO, To Big Pharma

    Daniel Skovronsky, M.D., Ph.D., is the SVP of clinical and product development at Eli Lilly and Company. But prior to taking on this role, he held the title of CEO of Avid Radiopharmaceuticals — a company he founded in Philadelphia while still a graduate student at the University of Pennsylvania. This article explores some of the differences between this executives past and present roles, and is a good prequel to the upcoming article that explores how he went about building a $300 million company.

  • Does The Biopharmaceutical Industry Need To Broaden Its Horizons?

    When I interviewed Axovant Sciences CEO David Hung, one of the questions posed was sparked by our discussion of his experience at Pro-Duct Health and his invention of a microcatheter for early detection of ductal breast cancer in women. As he explained his medical device invention, Hung commented, “I don’t want to be just medicines, or just devices, or anything like that.”

  • What Might Be The Best Predictor Of Future Performance At Axovant Sciences?

    Chief Editor Rob Wright recently conducted an in-person interview with David Hung, formerly of Medivation and current  CEO of Axovant Sciences. Though many may credit the FDA’s approval of Medivation’s Xtandi (enzalutamide) as being the primary driver behind Hung’s rise, Wright argues that there are a number of other predictors that should be evaluated when anticipating future success.

More From Beyond The Printed Page

LIFE SCIENCE LEADER BLOGS

  • Why <em>Every</em> Company Needs A Bio Strategy
    Why Every Company Needs A Bio Strategy

    Today we stand on the precipice overlooking a new frontier — the century of biology, and businesses of all kinds need to be prepared to not only embrace what is coming, but have a strategy for how to leverage biology for the betterment of their businesses and the good of the planet.

  • What Is BIO Hoping To See Among Session Submissions For 2018?
    What Is BIO Hoping To See Among Session Submissions For 2018?

    Life Science Leader Chief Editor Rob Wright is cochairing the 2018 BIO educational program planning committee. In this blog he talks about why this was the earliest the planning committee has ever met and what you can do to submit interesting and novel session proposals that will get the attention of the committee.

More From Life Science Leader Blogs

@LIFESCILEADER1